Wave Life Sciences Ltd. - Ordinary Shares (WVE)

Wave Life plans a 2026 NDA filing for WVE-N531 after positive Phase 2 data in Duchenne muscular dystrophy, showing functional gains and biomarker improvements.

This stock currently has a good balance of risk and potential rewards.

Korro Bio is lagging Wave Life Sciences. But an analyst says it could ultimately be the leader.

These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio?

Wave Life Sciences' WVE-006 demonstrates first-ever RNA editing in humans for alpha-1 antitrypsin deficiency, showing favorable safety and efficacy in early trial results. GSK holds global license rights with $525 million in milestone potential.

The company is testing its new technology in patients with a genetic disease that impacts the lungs.

These two could become direct competitors relatively soon.

Wave Life Sciences reveals positive interim data from its Phase 2 FORWARD-53 study on WVE-N531 for Duchenne muscular dystrophy patients. Results show improved muscle health, dystrophin production, and safety, with no severe side effects. Wave anticipates trial completion in Q1 2025.

William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1 antitrypsin deficiency.

WVE stock results show that WAVE Life Sciences missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.